Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $YMAB
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/18/2024 | $23.00 | Outperform | Oppenheimer |
8/16/2024 | $20.00 | Overweight | Cantor Fitzgerald |
6/28/2024 | $21.00 | Buy | Truist |
5/10/2023 | $5.00 → $13.00 | Neutral → Outperform | Wedbush |
4/3/2023 | Buy → Neutral | Guggenheim | |
1/27/2023 | $4.00 | Equal-Weight → Underweight | Morgan Stanley |
1/5/2023 | Outperform → Market Perform | Cowen | |
12/2/2022 | $23.00 → $5.00 | Buy → Neutral | BofA Securities |
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target
Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00
Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target
Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage on Y-mAbs Therapeutics with a new price target
Truist initiated coverage of Y-mAbs Therapeutics with a rating of Buy and set a new price target of $21.00
Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SEC Form 144 filed by Y-mAbs Therapeutics Inc.
144 - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc.
424B5 - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC
Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)